Point72 (DIFC)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Point72 (DIFC)’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,382	Closed	-$1.24M	–	2200
2025 Q1	$1.24M	Buy	9,382 +6,430	+218%	+$801K	0.05%	419
2024 Q4	$247K	Buy	+2,952	New	+$243K	0.01%	827
2024 Q3	–	Sell	-20,385	Closed	-$1.4M	–	1924
2024 Q2	$1.4M	Buy	+20,385	New	+$1.41M	0.05%	415

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Point72 (DIFC)'s ITCI Position: Q2 2025 in Review

Point72 (DIFC) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 9,382 shares — an estimated $1.24M sold.

Point72 (DIFC) first reported a position in ITCI in Q2 2024 and held it in 3 quarters. The position peaked at $1.4M in Q2 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Point72 (DIFC) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Point72 (DIFC) sold 9,382 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.24M.
Point72 (DIFC) first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 3 quarters.
Point72 (DIFC)'s Intra-Cellular Therapies Inc. position peaked at $1.4M in Q2 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Point72 (DIFC)'s 13F filing for Q2 2025, filed 14 Aug 2025.